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Abstract  
Addition of rituximab (R) to "CHOP" (cyclophosphamide, doxorubicin, vincristine, prednisone) 
chemotherapy improved outcome for diffuse large B-cell lymphoma (DLBCL) patients. Approximately 
40% of patients that received R-CHOP still succumb to disease due to intrinsic resistance or relapse.  
A potential negative regulator of DLBCL treatment outcome is the CD47 "don't eat me" immune 
checkpoint. To delineate the impact of CD47, we used a clinically and molecularly well-annotated 
cohort of 939 DLBCL patients, comprising both germinal center B cell (GCB) and non-GCB DLBCL 
subtypes, treated with either CHOP or R-CHOP. High (above median) CD47 mRNA expression 
correlated with a detrimental effect on overall survival (OS) when DLBCL patients received R-CHOP 
therapy (p=0.001), but not when receiving CHOP therapy (p=0.645). Accordingly, patients with low 
CD47 expression benefited most from addition of rituximab to CHOP (HR, 0.32; CI, 0.21-0.50;  P < 
0.001). This negative impact of high CD47 expression on OS after R-CHOP treatment was only evident 
in cancers of non-germinal center B-cell (GCB) origin (HR, 2.09; CI, 1.26-3.47; P = 0.004) and not in 
the GCB subtype (HR, 1.16; CI, 0.68-1.99; P = 0.58). This differential impact of CD47 in non-GCB and 
GCB was confirmed in vitro, as macrophage-mediated phagocytosis stimulated by rituximab was 
augmented by CD47-blocking antibody only in non-GCB cell lines. Thus, high expression of CD47 
mRNA limited the benefit of addition of rituximab to CHOP in non-GCB patients and CD47-blockade 
only augmented rituximab-mediated phagocytosis in non-GCB cell-lines. Patients with non-GCB 
DLBCL may benefit from CD47-targeted therapy in addition to rituximab. 
Introduction:  
Diffuse Large B-cell Lymphoma (DLBCL) is the most common form of lymphoma. DLBCL is an 
aggressive and heterogeneous disease that can be classified into germinal center B-cell–like (GCB), 
activated B cell–like (ABC) and unclassifiable DLBCL, with the latter two often being grouped together 
as non-germinal center B cell–like (non-GCB) [1]–[3]. The standard therapy for all DLBCL subtypes is 
chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) 
combined with the rituximab monoclonal antibody to CD20. Addition of rituximab to CHOP (R-CHOP) 
has improved progression free survival (PFS) and overall survival (OS) of DLBCL [4]. Nevertheless, 
~40% of DLBCL patients will develop resistance to R-CHOP and these patients have poor outcomes 
[5], [6]. Further, efficacy of R-CHOP differs between subclasses, with ABC DLBCL having a lower 5-
year progression free survival (PFS) than GCB DLBCL (40% vs. 74%) [7].  
Attempts to improve outcome of R-CHOP treatment with dose-intensified chemotherapy or new 
CD20 antibodies have so far not been successful  [8], [9] and the mechanisms that underlie resistance 
to rituximab treatment remain unclear. Rituximab has multiple modes of action that include 
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induction of antibody-dependent cellular phagocytosis (ADCP) [10], [11]. Resistance to ADCP has 
been attributed to aberrant activation of the innate immune checkpoint CD47/signal regulatory 
protein alpha (SIRPα). CD47 is a so-called “don’t eat me” signal that, upon binding to SIRPα expressed 
on phagocytes, triggers inhibitory signaling that limits phagocyte activity [12]. Correspondingly, 
overexpression of CD47 associates with poor prognosis in various cancers [13]–[16]. Blocking of the 
CD47-SIRPα interaction in preclinical murine xenograft models augments the anti-tumor activity of 
monoclonal antibodies, including that of rituximab [13].  
Based on these findings, CD47 blocking has emerged as an immunomodulatory therapy that is being 
evaluated in early clinical trials, among others in combination with rituximab (NCT02953509). Indeed, 
high expression of CD47 mRNA was associated with poor survival in DLBCL, positioning DLBCL as a 
candidate for CD47-targeted therapy. Combination therapy with CD47 mAb (5HuF9-G4 clone) and 
rituximab resulted in 40% OR (overall response) and 33% CR (complete response) of relapsed or 
refractory DLBCL patients [17]. However, for CD47 blocking to be useful in clinical treatment of 
DLBCL, DLBCL patients who might benefit from CD47 blocking therapy must be identified.  
In this study, we assembled a DLBCL transcriptome dataset comprising 939 clinically annotated 
DLBCL patients to delineate the impact of CD47 mRNA expression on CHOP and R-CHOP treatment in 
GCB and non-GCB DLBCL patients. Further, we defined in a preclinical setting whether these DLBCL 





Data acquisition, sample processing, quality control, probe selection and patient characteristics  
Publicly available raw microarray expression data of DLBCL samples from various platforms 
(Affymetrix HG-U133A (GPL96) and Affymetrix HG-U133 Plus 2.0 (GPL570)) were extracted from the 
Gene Expression Omnibus (GEO) as previously described [18]–[20] (Supplementary Table S1). Probe 
213857_s_at was used in the analyses. For patient characteristics see Supplementary Table S2.  
 
Statistics  
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High CD47 mRNA expression was defined by expression above median (10.00 log2 mRNA expression) 
as determined on the total 939 patient DLBCL cohort. Clinical parameters analyzed were overall 
survival (OS), defined as the time from primary diagnosis to death from any cause. Survivors were 
censored on the last date known to be alive or at 5 years of follow up. Univariate group comparisons 
were performed with the  test for categorical data, the independent t test for continuous data and 
Kaplan-Meier method and the log-rank test for survival data. The Cox proportional hazard model was 
used to determine relevance of clinical and pathological characteristics [age and international 
prognostic index (IPI)-score] for OS expressed as hazard ratios with 95% confidence intervals (CI). 
Multivariate Cox analysis with interactions was used to determine the effect of CD47 expression on 
survival after CHOP or R-CHOP treatment. These analyses were performed in all patients who were 
CHOP/R-CHOP–treated. To analyze impact of CD47 high or low mRNA expression in distinct DLBCL 
subtypes, GCB and non-GCB patient populations were analyzed. All analyses were tested two-sided 
and p-values < 0.05 were considered statistically significant. Analyses were performed using SPSS 
(version 25.0 Armonk, NY, IBM Corp.) or STATA 14 (StataCorp LP, College Station, TX).  
 
Cell lines and culture conditions 
DLBCL cell lines OCI-ly3 (non-GCB DLBCL), U-2932 (non-GCB DLBCL), SUDHL4 (GCB DLBCL), SUDHL6 
(GCB DLBCL), SUDHL10 (GCB DLBCL) were obtained from Deutsche Sammlung from Microorganism 
und Zellculturen, Braunschweig, Germany, and SUDHL2 (DLBCL non-GCB) was obtained from 
American Type Culture collection, Manassus, Virginia, US. All cell lines were cultured in RPMI-1640 
supplemented with 10% Fetal Calf Serum (FCS) at 37°C with 5% CO2 in a humidified atmosphere and 
in 1% Penicillin-Streptomycin (Lonza BioWhittaker) and 1% Glutamine (Lonza BioWhittaker). The cell 
line identity was checked periodically (~ each 6 months) by STR profiling. All cell lines were tested 
mycoplasm free on 12/23/2017). Experiments were performed within 4 months after start of culture 
and mycoplasm testing. The cells were tested with a PCR assay that detects 25 mycoplasma and 
acholeplasma species that include those that most commonly contaminate cell cultures. The 
following primers were used in the mycoplasm PCR; forward primer sequences (cgc ctg agt agt acg 
ttc gc, cgc ctg agt agt acg tac gc, tgc ctg agt agt aca ttc gc, tgc ctg ggt agt aca ttc gc, cgc ctg ggt agt aca 
ttc gc, cgc ctg agt agt atg ctc gc) Reverse primer sequences (gcg gtg tgt aca aga ccc ga ,gcg gtg tgt aca 
aaa ccc ga, gcg gtg tgt aca aac ccc ga)  
 
Generation and differentiation of human macrophages  
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Peripheral blood mononuclear cells were isolated from blood of healthy donors by density gradient 
centrifugation after informed consent. Monocytes were enriched by MACS sorting with CD14 
magnetic beads (Miltenyi Biotec). In brief, CD14+ cells were magnetically labeled with CD14 
microbeads and the suspension was loaded onto MACS column in a magnetic field. Only CD14+ cells 
were retained within the column and were subsequently eluted from the column. Next, CD14+ 
monocytes were differentiated to macrophages (M0) in RPMI1640-10% FBS supplemented with GM-
CSF (50 ng/mL) and M-CSF (50 ng/mL) for 7 days. Type 1 macrophages were generated by priming 
with LPS (100 ng/mL) and IFNγ (20 ng/mL) on day 8. Type 2 macrophage were generated by priming 
with IL-10 (20 ng/mL) for an additional 48 h. All cells were cultured with 5% CO2, 37°C. For each 
experiment, macrophages were harvested and the phenotype was verified by flow cytometry using 
cell surface markers CD14, CD68, and CD80.  
 
Macrophage phagocytosis assays  
Macrophages were pre-seeded in 96-well plates at a density of 1.5x10^4 cells/well and cultured for 
24h. DBLCL cells were labeled with cell proliferation dye V450 (Thermofisher) or CFSE (Thermofisher) 
according to manufacturer’s instructions. Subsequently, tumor cells were incubated with rituximab 
alone or rituximab in combination with human CD47 IgG4 antibody (Inhibrix) (both at 5 μg/ml) on ice 
for 1h. Labeled DLBCL cells were washed twice (with PBS) and added to pre-seeded macrophages at 
an effector-to-target ratio of 1 to 5. Mixed cultures were incubated for 3h at 37°C, after which non-
adherent DLBCL cells were removed by washing twice with PBS. Subsequently, phagocytosis was 
assessed by fluorescent microscopy (Leica, DM6000) by counting the number of adherent/stretched 
macrophages containing V450-labeled tumor cells per 100 macrophages, yielding the percentage 
phagocytosis. For phagocytosis of M1 macrophages, counting was performed based on stretched 
morphology of macrophages, whereas for M2 macrophages cells were counterstained with CD11b-PE 
antibody (clone, MEM-174, Immunotools) at room temperature for 45 minutes. In addition, the 
phagocytic index was calculated using the formula (number of tumor cells per macrophage/ total 
number of V450+ macrophages). Each condition was quantified by evaluating three randomly chosen 
fields of view. Statistical significance was evaluated using two-tailed paired Student t test. P-value 
<0.05 was considered statistically significant. 
 
Anti-human CD47 IgG4 (Inhibrix) 
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The sequence of the inhibrix antibody (clone Ab6.12) was obtained from US patent 





High expression of CD47 predicts survival in R-CHOP, but not CHOP-treated DLBCL patients  
In CHOP/R-CHOP–treated DLBCL patients, high expression of CD47 (i.e. above median) was 
associated with decreased overall survival (OS) compared to patients with low CD47 expression (i.e. 
below median) (HR, 1.63; CI, 1.20-2.00; p=0.0003), Supplementary Fig. S1A and for patient 
characteristics see Supplementary Table S2). However, when analyzing the CHOP-treated DLBCL 
patients separately, no significant difference in OS was observed between patients with high and low 
CD47 expression (Fig. 1A, p=0.645). In contrast, separate analysis of R-CHOP–treated patients 
identified that OS was significantly worse in patients with high expression of CD47 (Fig. 1B p=0.001). 
In a Cox proportional hazard model with interaction, high CD47 expression (compared to low) was 
associated with decreased OS, independent of IPI-score and age in R-CHOP–treated patients. The 5-
year OS in patients with high CD47 expression after R-CHOP treatment was 2-fold reduced compared 
to patients with low CD47 expression (Table 1, (HR, 2.1; CI, 1.39-3.25; p=0.001)). In contrast, 
expression of CD47 did not significantly impact the 5-year OS in DLBCL patients treated with CHOP 
(HR, 0.93; CI, 0.62-1.40, p=0.741). In multivariate analysis of R-CHOP–treated patients, IPI, – DLBCL 
cell-of-origin subtype and CD47 expression significantly affected the 5-year OS (Supplementary Table 
S3). Thus, CD47 expression predicts the OS in R-CHOP–treated but not CHOP-treated patients.  
Addition of rituximab to CHOP has resulted in a significant increase in survival of DLBCL patients (see 
also Supplementary Fig. S1B, (HR, 0.46; CI, 0.37-0.58; p<0.001)). We identified that, in patients with 
low CD47 expression, addition of rituximab to CHOP improved the 5-year OS 4-fold (Table 1, Fig. 1C. 
(HR,0.25; CI, 0.15-0.43; p<0.001). However, in patients with high CD47 expression, addition of 
rituximab to CHOP improved OS only 2-fold. (Table 1, Fig. 1D, (HR, 0.57; CI, 0.43-0.77;  p<0.001). 
Taken together, these data suggest that high expression of CD47 is associated with a limited 
therapeutic effect of rituximab upon treatment of DLBCL patients with CHOP.  
 
High expression of CD47 associated with poor response to R-CHOP only in non-GCB subgroup  
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In a subsequent analysis of CD47 expression within GCB and non-GCB DLBCL subtypes, mean 
expression of CD47 mRNA in non-GCB DLBCL patients was significantly higher than the mean in GCB 
DLBCL patients (Supplementary Fig. S2A,B p<0.0001). Further, and in line with literature, non-GCB 
DLBCL patients had a two-fold higher risk of death after R-CHOP treatment compared to GCB DLBCL 
patients ((HR, 1.9; CI, 1.27-2.90; p=0.002), Supplementary Fig. S3A, Supplementary Table S4 for 
multivariate analysis). In line with our analyses in the complete DLBCL study cohort, addition of 
rituximab to CHOP significantly improved survival in both GCB and non-GCB DLBCL patients 
(Supplementary Fig. S3B, C, p<0.0001).  
To assess the impact of CD47 expression on the outcome in non-GCB and GCB patients the OS in the 
cohort of R-CHOP–treated patients was studied. These analyses indicated that within the R-CHOP-
treated non-GCB DLBCL subgroup, patients with high CD47 expression had an inferior survival 
compared to patients with low CD47 expression (Fig. 2A, (HR, 1.9; CI, 1.44-3.26; p=0.015). Within this 
non-GCB subtype no difference of age or IPI score was observed between patients with high or low 
CD47 expression using univariate analysis (Supplementary Table S5, Age p=0.550, IPI p=0.594). In the 
GCB-DLBCL patient subgroup no difference was observed in OS between patients with high or low 
expression of CD47 (Fig. 2B, p=0.584). Taken together, these data indicate that high expression of 
CD47 predicts OS after R-CHOP treatment in the non-GCB DLBCL patient population and not in the 
GCB DLBCL patient population.  
To further assess the impact of DLBCL subtype on outcome in patients with low and high CD47 
expression next   the full cohort of R-CHOP–treated patients was studied. In patients defined as 
having low CD47 expression (e.g. below median), survival did not differ between GCB and non-GCB 
patients (Fig. 2C, p=0.7662). In contrast, in patients with high CD47 expression, non-GCB patients had 
worse OS compared to GCB patients (Fig. 2D, p=0.0006). Within the CD47-high population, the age 
and IPI-score were also significantly different between GCB and non-GCB population (Table 2). 
However, in multivariate analysis, correcting for age and IPI-score, non-GCB patients with high CD47 
expression still had a 2-fold increased risk of death compared to GCB patients with high CD47 
expression (Table 2, (HR, 2.09; CI, 1.26-3.47; p=0.004). Thus, only the non-GCB  DLBCL subtype 
negatively impacts survival of patients with high CD47 expression after R-CHOP treatment 
(Supplementary Fig. S3D). 
 
CD47 blockade promotes rituximab-mediated ADCP of non-GCB but not GCB DLBCL cells  
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As high expression of CD47 predicted survival only in the non-GCB subtype, we wondered whether 
CD47 blockade might also selectively facilitate rituximab-mediated phagocytosis in the non-GCB 
subtype of DLBCL only. To evaluate this hypothesis, non-GCB and GCB cell lines were mixed with 
allogeneic macrophages differentiated towards M1 or M2 phenotype and treated in vitro with the 
previously reported CD47 antibody Ab6.12 comprising human IgG4 (termed inhibrix) (for 
representative pictures see Fig. 3A). Human IgG4 does not trigger ADCP, thus allowing direct 
evaluation of the impact of CD47-blocking [21]. Treatment with inhibrix dose-dependently enhanced 
rituximab-mediated phagocytosis of non-GCB cell line U2932, but not of the GCB cell line SUDHL4 by 
M1-differentiated macrophages (Fig. 3B,C). Treatment with human IgG4 isotype control did not 
significantly (p>0.05) induce phagocytosis (Supplementary Fig. S4A, see Methods for statistics). This 
differential impact of CD47-blocking between GCB and non-GCB cell lines by M1 macrophages was 
detected in a larger cell panel, with rituximab-mediated phagocytosis being significantly augmented 
by inhibrix in 3 out of 3 non-GCB cell lines and in none of the 3 GCB cell lines (Fig. 3D). Inhibrix co-
treatment also increased the number of tumor cells ingested per macrophage, with increased 
numbers of phagocytosed cells per macrophage (i.e. phagocytic index, see method section for 
statistics) in non-GCB cells, but not in GCB cells (Fig. 3E). Thus, CD47 blockade using the human IgG4 
containing antibody inhibrix significantly (p<0.05) augmented rituximab-mediated phagocytosis by 
M1-differentiated macrophages in non-GCB cells, but not in GCB cells. In analogous experiments with 
M2-differentiated macrophages, co-treatment with inhibrix again only significantly augmented 
rituximab-mediated macrophage-mediated phagocytosis of non-GCB cell lines and not GCB cell lines 
(Fig. 3F), although in this case the impact on phagocytic index was minimal (Fig. 3G). Neither 
expression of CD20 nor expression of CD47 on the respective cell lines strongly correlated with 
experimental induction of phagocytosis (Supplementary Fig. S4B, C; r2 0.29 and 0.14 respectively). 
These in vitro data indicate that the therapeutic effect of rituximab may be increased by CD47 
blocking antibody in the non-GCB subtype of DLBCL only.  
 
Discussion  
Although addition of R to CHOP chemotherapy improves the treatment outcome in DLBCL patients,  
the data presented here demonstrate that patients with high expression of the “don’t eat me” signal 
CD47 benefited less from the addition of rituximab to CHOP than patients with low expression of 
CD47. CD47 expression only associated with poor survival after R-CHOP treatment in non-GCB DLBCL. 
Indeed, in multivariate analysis CD47 expression was an independent risk factor for outcome of non-
GCB but not for outcome of GCB DLBCL patients treated with R-CHOP. In line with these 
observations, macrophage-mediated phagocytosis of DLBCL cells upon rituximab treatment in vitro is 
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augmented by a CD47-blocking antibody in non-GCB cell lines, but not in GCB cell lines. The findings 
presented here suggest that only CD47 high expressing patients of the non-GCB subtype and not the 
GCB subtype will benefit from addition of CD47-antibody therapy to rituximab treatment.  
R-CHOP is the standard therapeutic regimen for DLBCL patients and resistance to R-CHOP associates 
with a dismal prognosis [22]. Resistance to rituximab has been attributed to inhibitory signals that 
limit its effector functions. Examples of resistance mechanisms include polymorphisms of the Fcγ 
receptor III on cytotoxic cells that limit antibody dependent cellular cytotoxicity (ADCC) [23], 
expression of complement inhibitory proteins [24], and upregulation of anti-apoptotic proteins (such 
as BCL-2) [25]. Here, we showed that expression of CD47 may be another contributor to resistance, 
specifically to induction of phagocytosis by rituximab. Attempts to enhance the efficacy of CD20-
targeting have included development of second-generation antibodies such as obinutuzumab. 
Compared to rituximab, obinutuzumab more effectively triggers direct cell death and induces 
phagocytosis [26]. However, obinutuzumab-CHOP failed to increase progression free survival 
compared to R-CHOP in untreated DLBCL patients [8]. Ofatumumab, a second generation anti-CD20 
with enhanced capacity to activate complement-mediated cytotoxicity, also failed to improve 
survival compared to rituximab in refractory DLBCL patients in the setting of salvage therapy [6]. 
Thus, for certain DLBCL patients, combination of rituximab or obinutuzumab treatment with CD47-
blocking therapy might be useful.  
In addition to the selective negative association of CD47 expression with non-GCB DLBCL survival in 
the clinical analysis, in vitro macrophage-mediated phagocytic removal of DLBCL cells upon rituximab 
treatment was only augmented by CD47-blocking antibody in non-GCB cell lines. In contrast, 
phagocytosis of GCB cell lines was not augmented by CD47 blocking antibody. This effect was 
observed in a panel of 3 GCB and 3 non-GCB cell lines. In a clinical study [17], treatment with anti-
CD47 (Hu5F9-G4) in combination with rituximab yielded a higher objective response rate in patients 
with ABC-DLBCL than in GCB-DLBCL patients (67% for ABC-DLBCL vs 17% for GCB-DLBCL). These data 
fit with our conclusions here, although follow-up studies in a larger cohort of patients will be 
required to address the impact of ABC and GCB subtype on CD47 therapy.  
The reason underlying this differential response to CD47-blocking in GCB versus non-GCB cell lines 
has yet to be defined, but may be related to differences in the balance of “don’t eat me” signals such 
as CD47 and “eat me” signals such as phosphatidyl serine on GCB and non-GCB cells. A candidate 
pro-phagocytic protein reported in this respect was SLAMF7, an eat-me signal initially described as a 
requisite for CD47 antibody-induced phagocytosis [27]. However, we have shown that DLBCL 
expression of SLAMF7 is not required for CD47-mediated phagocytosis [19]. An alternate candidate 
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pro-phagocytic protein is calreticulin, an ER protein that on stressed (cancerous) cells can be 
detected on the cell surface, where the balance between CD47 and calreticulin expression 
determines phagocytosis [28]. On the other hand, differential expression of don’t eat me signals, 
such as LILRB1, on macrophages and cognate receptors, such as MHC class I, on DBLCL cells may 
underlie GCB/non-GCB differences. In this respect, disruption of either MHC class I or LILRB1 
potentiated phagocytosis of tumor cells upon CD47 mAb treatment both in vivo and in vitro [29]. 
Non-GCB tumor cells are characterized by loss of tumor major histocompatibility complex class I [30], 
thus removal of the CD47 axis in this cell type may suffice to trigger phagocytosis. 
The clinical findings reported here on the negative association of CD47 expression upon R-CHOP 
treatment are in line with preclinical data on the potentiation of therapeutic antibodies by CD47 
blockade [13], [31], [32], where high CD47 expression inhibits antibody dependent cellular 
phagocytosis (ADCP) [33], [34]. These findings partly contrast with a report by Chao et al, in which 
high mRNA expression of CD47 in DLBCL was predictive of survival in both CHOP and R-CHOP-treated 
patients [13], with the same CD47 probe used in both studies. A likely explanation for this difference 
is the fact that Chao et al. used an optimal CD47 expression cut off to measure survival differences 
after CHOP treatment. Although giving  the most significant difference in survival between high and 
low CD47 expressing patients, this method resulted in disparate groups, with only 27 patients with 
high CD47 expression and 203 patients with low expression. In contrast, the median CD47 expression 
used as cutoff in the current study (as determined based on the complete study cohort; R-CHOP and 
CHOP-treated) guaranteed that high expression of CD47 was defined with the same threshold in all 
analyses (i.e., analyses of the total DLBCL cohort (939 patients), R-CHOP/CHOP analyses as in the 
GCB/non-GCB analyses). General survival outcomes for the subgroups GCB and non-GCB DLBCL and 
for CHOP versus R-CHOP–treated DLBCL patients were comparable to published data, suggesting that 
our selection procedure did not result in a selection bias.  
As referred to above, combination therapy including both CD47 targeting and rituximab has been 
reported for CD47 mAb 5HuF9-G4 and is being evaluated in a phase 1 trial with mAb CC-90002 in 
patients with advanced/refractory CD20+ B-cell Non-Hodgkin’s Lymphoma patients (NCT02367196). 
Based on the data presented, survival after treatment with rituximab in combination with CHOP 
chemotherapy is only impacted by high expression of CD47 in non-GCB DLBCL patients. In line with 
these data, only cell lines of the non-GCB subtype benefitted from combining rituximab with CD47 
blocking treatment in vitro. These results have implications for the interpretation and design of 
clinical trials for DLBCL. For example, we suggest that clinical trials with CD47-targeting therapeutics 
and rituximab in DLBCL should be stratified and specifically include the non-GCB subtype. Clinical 
trials are increasingly designed to evaluate subtype-specific DLBCL therapy, e.g. a clinical trial with 
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ibrutinib (NCT01855750) is only recruiting non-GCB DLBCL patients. Moreover, clinical trials with 
lenalidomide and bortezomib in combination with R-CHOP have demonstrated that non-GCB DLBCL 
patients especially benefit from these therapeutic improvements [35]. 
In summary, the data presented here support the implementation of anti-CD47 as a co-treatment 
with rituximab for DLBCL patients. Our data analysis as well as preclinical functional macrophage 
phagocytosis data indicate that non-GCB patients are likely to benefit from combined treatment of 
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Tables 
Table 1. Uni- and multivariate analysis with interaction to determine the effect of 
CHOP and R-CHOP treatment of DLBCL patients with high or low CD47 expression. 
*p-value of two-way interaction analysis between CD47 expression and treatment on 
overall survival of DLBCL patients. Abbreviations: OS, overall survival, IPI, international 
prognostic index, R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine and 
prednisolone. 
 Univariate analysis Multivariate analysis 
      
 Hazard P value Hazard P 95% CI 
 ratio  ratio value  
Age categorized      
<60 yr      
≥ 60 yr 1.759 0.000    
IPI categorized      
Low risk (0,1)      
Intermediate risk (2,3) 2.405 0.000    
High risk (4,5) 4.698 0.000    
high compared to low CD47 when      
treated with CHOP 1.093 0.645 0.934 0.741 [0.623-1.400] 
high compared to low CD47 when      
treated with R-CHOP 1.826 0.001 2.129 0.000 [1.394-3.252] 
Treatment effect of R-CHOP      
compared to CHOP in high CD47 0.541 0.000 0.573 0.000 [0.429-0.766] 
Treatment effect of R-CHOP      
compared to CHOP in low CD47 0.324 0.000 0.251 0.000 [0.148-0.425] 
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Table 2. Uni- and multivariate analysis of GCB and non-GCB patients with high 
CD47 expression. Comparison of GCB and non-GCB in high CD47 expressing 
patients treated with R-CHOP. Multivariate analysis were used to analyze the 
association of these prognostic markers with overall survival. Abbreviations: OS, overall 
survival, (non)GCB, (non) Germinal Center B-Cell, IPI, international prognostic index. 
 Univariate analysis  P value Multivariate analysis  
 CD47high  CD47high   
 GCB  non-GCB  
Hazard 
ratio                   P value              95% CI 
Age categorized    0.002     
<60 yr 72  93      
≥ 60 yr 68  171  1.011 0.961 [0.652-1.568] 
         
IPI categorized    0.031     
Low risk (0,1) 59  87      
Intermediate risk (2,3) 56  130  2.158 0.004 [1.288-3.617] 
High risk (4,5) 10  36   5.975 0.000 [3023411.039] 
risk of non-GCB vs.     2.088 0.004 [1.258-3.467] 
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Figure legends 
Figure 1. Association between CD47 expression and overall survival of DLBCL patients. 254 patients 
were treated with CHOP and 680 were treated with R-CHOP. The CHOP and R-CHOP–treated 
populations were sorted based on their CD47 expression (high CD47 is above median and low CD47 is 
below median expression of the whole cohort) and were used in the Kaplan Meijer curves (A, B). 
Comparison of CHOP with R-CHOP treatment effect in patients with low CD47 expression (C) and in 
high CD47 expression (D). 
 
Figure 2. CD47 expression is associated with survival only in non-GCB DLBCL patients. The R-CHOP–
treated patient population was divided into GCB and non-GCB groups, then sorted into high CD47 
expressing and low CD47 expressing groups. (A) Kaplan Meijer curves of R-CHOP–treated high and 
low CD47 expressing non-GCB DLBCL patients. (B) Kaplan Meijer curves of R-CHOP–treated high and 
low CD47 expressing GCB DLBCL patients. (C) Kaplan Meijer curves of R-CHOP–treated non-GCB and 
GCB DLBCL patients with low CD47 expression or (D) high CD47 expression. 
 
Figure 3. Rituximab-mediated phagocytosis of non-GCB, but not GCB, cell lines is augmented by 
CD47 mAb. (A) U2932 (non-GCB) tumor cells were fluorescent labelled and mixed with M1 or M2 
macrophages. In the presence of CD47mAb (Inhibrix) (10 μg/mL) or rituximab (2.5 μg/mL), U2932 
cells were phagocytosed by macrophages. Phagocytosis of (V450-labelled) cancer cells (white arrows) 
as well as adherent and non-phagocytosed cancer cells (yellow arrows) was visualized. (B) SUDHL4 
(GCB cell line) and (C) U2932 (non-GCB cell line) was treated with a dose increase of rituximab in the 
presence or absence of CD47mAb (10 μg/mL). (%) phagocytosis was defined as the number of 
macrophages that phagocytosed tumor cells divided by the total amount of macrophages. (D) M1-
mediated phagocytosis of a panel of GCB and non-GCB cell-lines after rituximab treatment alone or 
in combination with CD47mAb (inhibrix) (both 5 μg/mL). (E) Phagocytic index as determined for the 
GCB and non-GCB cell line experiments in D. (F) The same panel of cell-lines was used to evaluate 
phagocytosis of non-GCB and GCB cell-lines by M2 macrophages. (G) Phagocytic index determined 
for M2 phagocytosis experiment in panel F. Experiments were performed in triplicates with 
macrophages obtained from independent healthy donors. Abbreviations: R; rituximab, GCB; 
Germinal Center B-cell Like, INH; inhibrix. 
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